Suppr超能文献

人肝移植术后早期肝再灌注期肿瘤坏死因子-α、白细胞介素-6和内毒素的经肝代谢

Transhepatic metabolism of TNF-alpha, IL-6, and endotoxin in the early hepatic reperfusion period after human liver transplantation.

作者信息

Steininger R, Roth E, Függer R, Winkler S, Längle F, Grünberger T, Götzinger P, Sautner T, Mühlbacher F

机构信息

Department of Transplantation Surgery, University of Vienna, Austria.

出版信息

Transplantation. 1994 Jul 27;58(2):179-83.

PMID:8042235
Abstract

Several studies have shown that the postoperative course of cytokines such as TNF-alpha or IL-6 is predictive of rejection and infection after human orthotopic liver transplantation (OLT). The aim of this prospective clinical trial was to evaluate the impact of transhepatic metabolism of endotoxin (ET), tumor necrosis-factor-alpha (TNF-alpha), and interleukin-6 (IL-6) after hepatic ischemia/reperfusion on the postoperative graft function. In 13 consecutive elective adult OLT patients with primary grafts, we determined concentrations of ET, TNF-alpha, and IL-6 in the radial artery, portal vein, and right hepatic vein at 1, 4, 7, 10, and 13 min after reperfusion. Of the 13 patients, four had ET levels below the detection limit (< 10 ng/L), and one patient had extremely high ET concentrations (151 ng/L in the hepatic vein). In the remaining patients the mean ET levels were 26 +/- 14, 26 +/- 15, and 24 +/- 14 ng/L in the portal vein, hepatic vein, and in the radial artery, respectively. These values indicate that in patients with a moderately elevated ET level, no transhepatic concentration differences of ET exist. However, in the patient with severe endotoxemia, the liver was apparently an ET-producing organ (HV-P: 29 +/- 13 ng/L). TNF-alpha levels were not measurable in four patients, and varied between 15 and 72 pg/ml (portal vein) in the remaining patients. The transhepatic concentration differences (HV-P and HV-A, respectively) of patients with PNF or dysfunction were higher than in those with "good" or "excellent" graft function (HV-P: 160 +/- 122 pg/ml vs. 7.3 +/- 9.7 pg/ml; P < 0.01 and HV-A: 137 +/- 101 pg/ml vs. 3.9 +/- 12 pg/ml; P < 0.01, respectively). Arterial IL-6 levels were below 88 pg/ml (mean value: 31 +/- 20 pg/ml) at the beginning of the operation, and increased considerably in three patients during the anhepatic phase and after reperfusion. No clinical correlation was found with the transhepatic concentration differences of IL-6. We conclude that in OLT patients without infection no transhepatic ET exchange was documented. However, a stimulated hepatic TNF-alpha release seems to be predictive of the beginning of liver dysfunction.

摘要

多项研究表明,细胞因子如肿瘤坏死因子-α(TNF-α)或白细胞介素-6(IL-6)的术后进程可预测人类原位肝移植(OLT)后的排斥反应和感染。这项前瞻性临床试验的目的是评估肝缺血/再灌注后内毒素(ET)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)的经肝代谢对术后移植肝功能的影响。在13例连续择期接受原发性肝移植的成年患者中,我们在再灌注后1、4、7、10和13分钟测定了桡动脉、门静脉和右肝静脉中ET、TNF-α和IL-6的浓度。13例患者中,4例ET水平低于检测限(<10 ng/L),1例患者ET浓度极高(肝静脉中为151 ng/L)。其余患者门静脉、肝静脉和桡动脉中的平均ET水平分别为26±14、26±15和24±14 ng/L。这些值表明,在ET水平中度升高的患者中,不存在ET的经肝浓度差异。然而,在严重内毒素血症患者中,肝脏显然是一个产生ET的器官(肝静脉-门静脉:29±13 ng/L)。4例患者的TNF-α水平不可测,其余患者的TNF-α水平在15至72 pg/ml之间(门静脉)。原发性无功能(PNF)或功能障碍患者的经肝浓度差异(分别为肝静脉-门静脉和肝静脉-动脉)高于移植肝功能“良好”或“优秀”的患者(肝静脉-门静脉:160±122 pg/ml对7.3±9.7 pg/ml;P<0.01;肝静脉-动脉:137±101 pg/ml对3.9±12 pg/ml;P<0.01)。手术开始时动脉IL-6水平低于88 pg/ml(平均值:31±20 pg/ml),3例患者在无肝期和再灌注后显著升高。未发现与IL-6的经肝浓度差异存在临床相关性。我们得出结论,在无感染的OLT患者中,未记录到经肝ET交换。然而,肝脏TNF-α释放的激活似乎可预测肝功能障碍的开始。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验